Valuation
- Market cap
- 27,082,000
- Revenue TTM
- $0
- Net income TTM
- $-1,070,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- -0.32
Trading
- Volume
- 148,000
- Avg volume
- 124,832
- Day's range
- $0.15 – $0.16
- Shares out
- 170,115,000
- Stochastic %K
- 7%
- Beta
- 0.21
- Analysts
- Strong Buy
- Price target
- —
Company profile
BetterLife Pharma Inc., a biotechnology company, engages in the development of psychedelic-derived compounds. It focuses on developing and commercializing BETR-001, a non-hallucinogenic and non-controlled LSD derivative to treat neuro-psychiatric and neurological disorders. Its products also comprise MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and MM-003...
Show more
BetterLife Pharma Inc., a biotechnology company, engages in the development of psychedelic-derived compounds. It focuses on developing and commercializing BETR-001, a non-hallucinogenic and non-controlled LSD derivative to treat neuro-psychiatric and neurological disorders. Its products also comprise MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and MM-003, a patent pending proprietary interferon alpha-2b inhalation formulation. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.
- Industry
- Biotechnology
- Sector
- Healthcare
- Website
- https://www.abetterlifepharma.com
- Address
- 1275 West 6th Avenue, Suite 300, Vancouver, Canada
Latest news
No headlines yet.
